1. Apoptosis Anti-infection Immunology/Inflammation
  2. Ferroptosis HCV Apoptosis COX
  3. Deferiprone

Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study.

For research use only. We do not sell to patients.

Deferiprone Chemical Structure

Deferiprone Chemical Structure

CAS No. : 30652-11-0

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
500 mg USD 50 In-stock
1 g USD 60 In-stock
5 g USD 70 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 31 publication(s) in Google Scholar

Other Forms of Deferiprone:

Top Publications Citing Use of Products

31 Publications Citing Use of MCE Deferiprone

View All COX Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study[1][2][3][4][5][6][7][8].

In Vitro

Deferiprone (66-660 μM, 48-96 h) has a significant inhibitory effect on proliferation in TRAMP-C2, Myc-CaP, and 22rv1 cells[1].
Deferiprone (100 μM, up to 192 h) inhibits cell migration in TRAMP-C2, Myc-CaP, and 22rv1 cells[1].
Deferiprone (100 μM, 24 h) reduces the expression and activity of m-Acon in TRAMP-C2, Myc-CaP, and 22rv1 cells[1].
Deferiprone (up to 1μM, 0.5-24 h) decreases the free iron in thalassemic red blood cells[2].
Deferiprone (10 mins) inhibits human platelet aggregation stimulated by AA and ADP and epinephrine and collagen, with the IC50 values of 0.24, 0.25, 3.36 and 3.73 mM, respectively[3].
Deferiprone (0.1-3.2 μM, 5 mins) inhibits COX-1 activity with the IC50 value of 0.33 μM[3].
Deferiprone (4 mM, 5 mins) preventes ADP-induced formation of cAMP[3].
Deferiprone (156.25 μg/mL, 24 h) enhances survival rate and reduces LDH Levels and displays normal cell morphology in aged Fibroblasts[4].
Deferiprone (25μM, 6 h) amplifies the antibacterial activity of conventional antibiotics against S. epidermidis[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: TRAMP-C2, Myc-CaP, and 22rv1 cells
Concentration: 0, 16, 30, 66, 100, 160, 300, 660 μM
Incubation Time: 48 h, 72 h
Result: Showed a cytostatic effect in three cell lines with an IC50 and IC90 values of about 50 and 100 μM, respectively.

Cell Migration Assay [1]

Cell Line: TRAMP-C2, Myc-CaP, and 22rv1 cells
Concentration: 100 μM
Incubation Time: 0 to 30 h for TRAMP-C2, and Myc-CaP; 0 to 192 h for 22rv1
Result: Inhibited cell migration starting at different time points for each cell line, ranging from 12 h in TRAMP-C2 cell to 48 h in 22rv1 cells, and 30 h in Myc-CaP cells.

Western Blot Analysis[1]

Cell Line: TRAMP-C2, Myc-CaP, and 22rv1 cells
Concentration: 100 μM
Incubation Time: 24 h
Result: Reduced the expression of m-Acon, by 2-fold in Myc-CaP and 22 rv1 cells and decreased by 79% in TRAMP-C2 cells.
In Vivo

Deferiprone (100 mg/kg/daily for i.g., 4 weeks) has a neuroprotective effect in the rTg(tauP301L)4510 mouse model of tauopathy[6].
Deferiprone (50-200 mg/kg/daily for p.o., 5-10 day) reduces the nephrotoxicity in Cisplatin (HY-17394)-induced rat acute renal failure[7].
Deferiprone (13.82, 27.64 mg/kg/d for i.g., 4 weeks) exhibits anti- apoptosis and neuroprotective activity in rat Alzheimer’s disease model[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: The rTg(tauP301L)4510 mouse model of tauopathy[6].
Dosage: 100 mg/kg/daily, 4 weeks
Administration: Intragastric administration (i.g.)
Result: Improved Y-maze and open field performance, and decreased 28% iron levels in brain, and reduced AT8-labeled p-tau within the hippocampus in transgenic tau mice.
Animal Model: Cisplatin(HY-17394)-induced rat acute renal failure model [7]
Dosage: 50, 100, 200 mg/kg, 5-10 day
Administration: Oral administration
Result: Reduced the creatinine, BUN, malondialdehyde, iron concentrations, and the amounts of TfR, and indreased the levels of HIF-1a and related anti-apoptotic genes expression in Cisplatin (HY-17394)-injected animals.
Animal Model: Aluminium-linked apoptosis in rat hippocampus model (Alzheimer’s disease model) [8]
Dosage: 13.82, 27.64 mg/kg/d, 4 week
Administration: Intragastric administration lasting 6 days with 1 day interval per week
Result: Decreased the apoptosis and the expression of Caspase-3 and Bax, and increased the expression of Bcl-2 in Aluminium-linked apoptosis in rat hippocampus.
Clinical Trial
Molecular Weight

139.15

Formula

C7H9NO2

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1C(O)=C(C)N(C)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 7.14 mg/mL (51.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 3.33 mg/mL (23.93 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 7.1865 mL 35.9324 mL 71.8649 mL
5 mM 1.4373 mL 7.1865 mL 14.3730 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 0.71 mg/mL (5.10 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 0.71 mg/mL (5.10 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 10 mg/mL (71.86 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.95%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 7.1865 mL 35.9324 mL 71.8649 mL 179.6622 mL
5 mM 1.4373 mL 7.1865 mL 14.3730 mL 35.9324 mL
10 mM 0.7186 mL 3.5932 mL 7.1865 mL 17.9662 mL
15 mM 0.4791 mL 2.3955 mL 4.7910 mL 11.9775 mL
20 mM 0.3593 mL 1.7966 mL 3.5932 mL 8.9831 mL
DMSO 25 mM 0.2875 mL 1.4373 mL 2.8746 mL 7.1865 mL
30 mM 0.2395 mL 1.1977 mL 2.3955 mL 5.9887 mL
40 mM 0.1797 mL 0.8983 mL 1.7966 mL 4.4916 mL
50 mM 0.1437 mL 0.7186 mL 1.4373 mL 3.5932 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Deferiprone
Cat. No.:
HY-B0568
Quantity:
MCE Japan Authorized Agent: